Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
BRISBANE, Calif., March 09, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.
The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
